The development is the result of years of work and collaboration with other Norwegian and international researchers, including vaccine experts Gunnveig Grødeland and Fridtjof Lund-Johansen (PRIMA).
“Our data are robust and very promising,” says Andersen. “This enables the concept to move forward toward human trials, ideally in collaboration with industry and authorities.”
He emphasizes the need for preparedness against future epidemics or pandemics. Unlike traditional injections, this vaccine targets mucosal surfaces—where infections typically begin—by combining viral proteins with engineered albumin to enhance immune responses. The vaccine concept showed full protection in mice and could be adapted for various pathogens.
The study was led by PhD students Aina Karen Anthi and Anette Kolderup together with Jan Terje Andersen, and funded by the University of Oslo’s SPARK program, the Research Council of Norway, South-Eastern Norway Regional Health Authority, and CEPI.
Read more about the study in the following press release and news stories.
https://www.eurekalert.org/news-releases/1082398
https://medwatch.no/nyheter/legemidler_biotek/article18137289.ece
https://www.vg.no/forbruker/i/KMAVk7/ny-vaksine-det-er-nesten-for-godt-til-aa-vaere-sant